Navigation Links
National Survey Shows Most Women Are Not Satisfied With Their Progesterone Treatment

First New Progesterone Supplement in a Decade Debuts As a More Convenient


PARSIPPANY, N.J., Nov. 12 /PRNewswire/ -- According to a nationwide survey of 350 women conducted on the American Fertility Association (AFA) Web site, few women undergoing an Assisted Reproductive Technology (ART) treatment for infertility, such as in vitro fertilization (IVF), realize that as they approach the finish line comes another treatment -- progesterone supplementation. This extra boost of progesterone, which supports embryo implantation and early pregnancy, is extremely important for a successful pregnancy. The survey, Progesterone Therapy: The Patient Perspective, was supported by an educational grant from Ferring Pharmaceuticals.

"Progesterone supplementation is a rigorous process that women in ART treatments must undergo for up to 10 weeks to improve their chances of pregnancy," said Pamela Madsen, AFA Executive Director. "One clear and disturbing conclusion from the survey is that there should be far more dialog between patients and their doctor about this critical aspect of treatment and the various therapy choices."

Progesterone Therapy: The Patient Perspective

Surprisingly, many patients did not know about progesterone therapy and product options before they started treatment. For 44 percent, their doctor or nurse did not explain progesterone therapy. Nearly all (94 percent) said they had no input into the selection of a product. Typically, they use whatever the doctor recommends.

Most of the women surveyed (86 percent) were not completely satisfied with their progesterone treatment, and 80 percent feel there is a need for a more patient-friendly option. Nearly all said that if they knew there was a new product available that was just as effective as current therapies, but more comfortable and convenient, they would ask their doctor about it.

The majority (nearly two-thirds) used intramuscular progesterone-in-oil injections typically given by a partner, which can be quite painful. In fact, 69 percent found them painful, 61 percent experienced moderate to very severe side effects, and 71 percent said the injections were inconvenient. Typical descriptions were: "a painful necessary evil," "like injecting yourself with mud," and "Big needle. Shot site can get very sore and expect bruising."

The majority of women (78 percent) who used progesterone suppositories said they leaked. Thirty four percent said the suppositories caused irritation and nearly half found them awkward to administer. A third experienced moderate to very severe side effects.

Most women who took gels and vaginal capsules found them messy and leaky. Of the 11 percent (37 people) who used a progesterone gel, more than three- quarters experienced gel build-up, a common problem with this form. Moderate to very severe side effects occurred with 40 percent of gel users, and one in three (28 percent) women who took progesterone capsules vaginally.

A new progesterone supplement, ENDOMETRIN(R) (progesterone) Vaginal Insert, 100 mg, was recently approved by the U.S. Food and Drug Administration (FDA), giving women the first new progesterone treatment option in a decade. Developed as a more convenient, patient-friendly treatment, ENDOMETRIN tablets are vaginally inserted with a disposable applicator two or three times daily, from the day of oocyte retrieval to about 10 weeks of pregnancy. Results of the largest IVF trial in the world, conducted at 25 U.S. centers in 1,211 women, showed that ENDOMETRIN provides unprecedented support in the final phase of ART treatment, based on high continuing pregnancy and live birth rates.

Research by Ferring Pharmaceuticals, manufacturer of ENDOMETRIN, found that what patients liked most about ENDOMETRIN is that it is easy to administer, convenient, painless (no injection), and less messy than suppositories. Nearly 80 percent would recommend it to a friend.


ENDOMETRIN administered as a progesterone vaginal insert is indicated to support embryo implantation and early pregnancy by supplementation of corpus luteal function as part of an Assisted Reproductive Technology (ART) treatment for infertile women.

Only physicians thoroughly familiar with infertility treatment should prescribe ENDOMETRIN. In clinical trials (n=860), adverse reactions that occurred at a rate greater than or equal to two percent included: uterine spasm (3% to 4%) and vaginal bleeding (3%). Vaginal irritation, itching, burning or discomfort, urticaria, and peripheral edema were reported at an incidence of less than two percent. ENDOMETRIN is expected to have adverse reactions to other drugs containing progesterone (breast tenderness, bloating, mood swings, irritability, and drowsiness).

About Ferring Pharmaceuticals

Ferring Pharmaceuticals, part of the Ferring Group, a privately owned, international pharmaceutical company, manufactures and markets the largest family of fertility treatments of any manufacturer in the U.S. The Company markets BRAVELLE(R) (urofollitropin for injection, purified), MENOPUR(R) (menotropins for injection, USP), REPRONEX(R) (menotropins for injection, USP), NOVAREL(R) (chorionic gonadotropin for injection, USP) and ENDOMETRIN in the U.S. to infertility specialists and their patients. Ferring also offers the Q-CAP(TM), the first and only needle-free reconstitution device, for use with its fertility treatments.

Ferring's line of orthopaedic and urology products includes EUFLEXXA(TM), hyaluronic acid for pain from osteoarthritis in the knee. Other products include ACTHREL(R) (corticorelin ovine triflutate for injection) for the differential diagnosis of Cushing's syndrome and DESMOPRESSIN ACETATE in injectable and rhinal tube forms for the treatment of diabetes insipidus and primary nocturnal enuresis.

The Ferring Group specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, urology, gastroenterology, obstetrics/ gynecology and infertility. For more information, call 888-337-7464 or visit or

Please contact Andrea Preston for full prescribing information for ENDOMETRIN.

SOURCE Ferring Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Brazilian National Biosafety Technical Committee Approves Monsanto Company Insect-Protected Corn Trait
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. Michael Troullis Appointed Chief Financial Officer of Quintiles Transnational Corp.
4. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
5. The Government of Quebec and the New Canadian Government Invest in the Creation of an International Biobank
6. International Isotopes Inc. Announces Completion of an Exclusive Distributor Agreement for Sales of New Style Transportation Containers
7. Arrow International Files and Mails Definitive Proxy Materials
8. Niceware International Announces Licensed Vendor Status with ICCBBA, Inc. to Provide ISBT 128-compliant Software
9. DuPont, Genencor International and Tate & Lyle Honored for Groundbreaking Work in Developing Bio-PDO(TM)
10. Viragen International to Reverse Split Its Common Stock
11. Tutogen Medical, Inc. and Zimmer Holdings, Inc. Announce Agreement for International Distribution of Biological Products
Post Your Comments:
(Date:11/24/2015)... /CNW Telbec/ - ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: ... Pierre Laurin , President and Chief Executive Officer of ProMetic, ... Jaffray 27 th Annual Healthcare Conference to be held ... st , at 8.50am (ET) and ProMetic,s ... day. The presentation will be available live via a webcast ...
(Date:11/24/2015)... and NEW YORK , November ... irst investment by Bristol-Myers Squibb in a European ... Bristol-Myers Squibb Company in which the companies will ... in immuno-oncology and other areas of unmet medical need. The ... in LSP 5, the latest LSP fund. This is the ...
(Date:11/23/2015)... OAKS, Calif., Nov. 23, 2015   Ceres, Inc ... announced today financial results for the fiscal year ended ... business. --> --> ... commercializing forage and feed products with a better balance ... company signed distribution agreements with several leading crop input ...
(Date:11/23/2015)... -- The royalty-free a greement a ... daclatasvir for 112 low- and m iddle-i ... --> The Medicines Patent Pool (MPP) today ... an agreement with Bristol-Myers Squibb for daclatasvir, a novel direct-acting ... the HCV virus.  The royalty-free licence will enable generic manufacture ...
Breaking Biology Technology:
(Date:11/12/2015)... 12, 2015  A golden retriever that stayed healthy ... (DMD) has provided a new lead for treating this ... Broad Institute of MIT and Harvard and the University ... Cell, pinpoints a protective gene ... disease,s effects. The Boston Children,s lab of Lou ...
(Date:11/12/2015)... , Nov. 11, 2015   Growing need ... analytical tools has been paving the way for ... determination of discrete analytes in clinical, agricultural, environmental, ... being predominantly used in medical applications, however, their ... sectors due to continuous emphasis on improving product ...
(Date:11/10/2015)... 10, 2015  In this report, the ... of product, type, application, disease indication, and ... report are consumables, services, software. The type ... biomarkers, efficacy biomarkers, and validation biomarkers. The ... diagnostics development, drug discovery and development, personalized ...
Breaking Biology News(10 mins):